Odyssey Therapeutics (ODTX)
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includ...
- Open
- 22.520
- High
- 24.660
- Low
- 22.400
- Prev. Close
- 21.950
- Volume
- 226.12K
- Turnover
- 5.43M
- Avg Price
- 24.024
- Bid/Ask Ratio
- 1.82%
- Amplitude
- 10.30%
- 52wk High
- 24.660
- Volume Ratio
- 1.00
- Turnover Ratio
- 1.46%
Odyssey Therapeutics Analyst Rating
View moreForecast & Rating
Aug 10, 2026Price forecast
$33.0036.08%
Forecast & RatingStrong buy
5analysts
- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · Aug 9 at 02:30 PM
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands
- Market Beat · Aug 7 at 11:42 AM
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co.
- Pharmaceutical Technology · Aug 7 at 04:10 AM
Evotec and Odyssey collaborate on AI-enabled R&D
- rttnews · Aug 6 at 03:55 AM
Biotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS
- StockTitan · Aug 5 at 05:16 PM
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases | EVO Stock News
- PUBT · Aug 4 at 06:07 AM
Odyssey Therapeutics Q2 FY26 net loss widens to $52.8 million
